Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Other Accumulated Expenses (2016 - 2024)

Historic Other Accumulated Expenses for Novartis Ag (NVSEF) over the last 16 years, with Q1 2024 value amounting to -$23.0 million.

  • Novartis Ag's Other Accumulated Expenses fell 36000.0% to -$23.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was -$23.0 million, marking a year-over-year decrease of 36000.0%. This contributed to the annual value of $516.0 million for FY2023, which is 3827.75% down from last year.
  • Latest data reveals that Novartis Ag reported Other Accumulated Expenses of -$23.0 million as of Q1 2024, which was down 36000.0% from $516.0 million recorded in Q4 2023.
  • In the past 5 years, Novartis Ag's Other Accumulated Expenses ranged from a high of $836.0 million in Q4 2022 and a low of -$113.0 million during Q3 2021
  • Its 5-year average for Other Accumulated Expenses is $306.3 million, with a median of $137.0 million in 2021.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 46371.68% in 2022, then crashed by 36000.0% in 2024.
  • Quarter analysis of 5 years shows Novartis Ag's Other Accumulated Expenses stood at $749.0 million in 2020, then decreased by 17.36% to $619.0 million in 2021, then skyrocketed by 35.06% to $836.0 million in 2022, then crashed by 38.28% to $516.0 million in 2023, then plummeted by 104.46% to -$23.0 million in 2024.
  • Its Other Accumulated Expenses stands at -$23.0 million for Q1 2024, versus $516.0 million for Q4 2023 and -$5.0 million for Q1 2023.